Study summary
An anti-inflammatory drug, ibudilast, did not reduce heavy drinking
What was tested
Ibudilast, a neuroimmune modulator, or placebo for 12 weeks in treatment-seeking adults with moderate or severe alcohol use disorder.
What they found
- Heavy drinking days did not differ from placebo.
- Inflammation markers did not change.
What it means
Brain-inflammation drugs remain under study but this one did not work overall.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.